Victoria makes Australia’s first mRNA vaccine candidate

by

Excerpt

In just five months, Victorian scientists and manufacturers developed Australia’s first mRNA COVID-19 vaccine candidate — the country’s first ever mRNA drug product – allowing clinical trials to start in the new year.

Article Summary

In just five months, Victorian scientists and manufacturers developed Australia’s first mRNA COVID-19 vaccine candidate — the country’s first ever mRNA drug product – allowing clinical trials to start in the new year.

The Peter Doherty Institute for Infection and Immunity (Doherty Institute) – a joint venture partnership between the University of Melbourne and the Royal Melbourne Hospital – has produced 450 doses of the COVID-19 vaccine candidate in Boronia, allowing 124 people to participate in Phase 1 clinical trials run by the Doherty Institute.

The trial’s results are due in late 2022, thanks to funding from the Australian government’s Medical Research Future Fund.

The Victorian government invested $5 million into the vaccine candidate and dedicated equipment was transported from Canada to the producer, IDT Australia. The machine sterilised the product and filled vials with mRNA vaccine after processing nanoparticles into final liquid medication form.

The mRNA-based vaccination breakthrough highlights Victoria’s leadership in the mRNA industry. Victoria is one of the few places in the world with the potential to design and manufacture mRNA treatments and vaccines.

The initiative was conducted by mRNA Victoria in cooperation with MIPS, the Doherty Institute, and IDT Australia – a ground-breaking combination between Victoria’s renowned medical research and manufacturing industries.

Source: University of Melbourne , 2021

Comments

Leave A Comment

Leave a Reply

Your email address will not be published.

bag